Abemaciclib is an orally active inhibitor of CDK4/6 that is indicated for HR+/HER2− BC patients, in combination with an AI or fulvestrant, depending on the clinical setting [1,12,13,14]. The gene discussed is CDK4; the disease is breast cancer.